BRCA1 and BRCA2 are tumor supressor proteins with key role in the maintenance of genomic integrity through the regulation of diverse cellular processes, including DNA damage repair by homologous recombination (HR). A number of BRCA1/2 mutations have also been associated with breast, ovarian, pancreatic and prostate cancer predisposition [Raimundo et al. 2020]. We aim to identify inhibitors of BRCA1/2-mediated HR activity to be used as single agents or in combination therapy in breast, ovarian and pancreatic cancers, whose therapy remains a challenge. Nevertheless, it is also expected to identify reactivators (able to restore wild-type-like activity) of mutBRCA1/2, to reduce cancer risk in mutBRCA1/2 carriers.